MSTN and type 1 diabetes mellitus: However, what remains poorly described is a comprehensive and integrative assessment of myostatin deletion within T1D, with an emphasis on its utilization as a potential pharmacological target in the therapeutic treatment of the disease, and this was the focus of this study.